Cargando…

Evolution of the Experimental Models of Cholangiocarcinoma

Cholangiocarcinoma (CCA) is a rare, aggressive disease with poor overall survival. In advanced cases, surgery is often not possible or fails; in addition, there is a lack of effective and specific therapies. Multidisciplinary approaches and advanced technologies have improved the knowledge of CCA mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Massa, Annamaria, Varamo, Chiara, Vita, Francesca, Tavolari, Simona, Peraldo-Neia, Caterina, Brandi, Giovanni, Rizzo, Alessandro, Cavalloni, Giuliana, Aglietta, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463907/ https://www.ncbi.nlm.nih.gov/pubmed/32824407 http://dx.doi.org/10.3390/cancers12082308

Ejemplares similares

Paclitaxel Restores Sensitivity to Chemotherapy in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma
por: Massa, Annamaria, et al.
Publicado: (2022)

Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patient
por: Cavalloni, Giuliana, et al.
Publicado: (2015)

Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma
por: Cavalloni, Giuliana, et al.
Publicado: (2016)

Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to Gemcitabine
por: Varamo, Chiara, et al.
Publicado: (2019)

A Novel Multidrug-Resistant Cell Line from an Italian Intrahepatic Cholangiocarcinoma Patient
por: Peraldo-Neia, Caterina, et al.
Publicado: (2021)

Proteomic analysis identifies deregulated metabolic and oxidative-associated proteins in Italian intrahepatic cholangiocarcinoma patients
por: Cavalloni, Giuliana, et al.
Publicado: (2021)

Gene and microRNA modulation upon trabectedin treatment in a human intrahepatic cholangiocarcinoma paired patient derived xenograft and cell line
por: Peraldo Neia, Caterina, et al.
Publicado: (2016)

Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation
por: Cavalloni, Giuliana, et al.
Publicado: (2016)

Assessment of a High Sensitivity Method for Identification of IDH1 R132x Mutations in Tumors and Plasma of Intrahepatic Cholangiocarcinoma Patients
por: Peraldo-Neia, Caterina, et al.
Publicado: (2019)

Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures
por: Rizzo, Alessandro, et al.
Publicado: (2020)

Asbestos and Intrahepatic Cholangiocarcinoma
por: Brandi, Giovanni, et al.
Publicado: (2020)

Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer
por: Peraldo-Neia, Caterina, et al.
Publicado: (2011)

Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models
por: Peraldo-Neia, Caterina, et al.
Publicado: (2014)

Mutational Landscape of Cholangiocarcinoma According to Different Etiologies: A Review
por: Tavolari, Simona, et al.
Publicado: (2023)

Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas
por: Pignochino, Ymera, et al.
Publicado: (2010)

Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue
por: Brandi, Giovanni, et al.
Publicado: (2023)

Fluoropyrimidine-induced cardiotoxicity in colorectal cancer patients: a prospective observational trial (CHECKPOINT)
por: Lombardi, Pasquale, et al.
Publicado: (2022)

Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma
por: Peraldo-Neia, C., et al.
Publicado: (2018)

Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies
por: Brandi, Giovanni, et al.
Publicado: (2015)

Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR
por: Peraldo-Neia, Caterina, et al.
Publicado: (2018)

Exposure to Asbestos and Increased Intrahepatic Cholangiocarcinoma Risk: Growing Evidences of a Putative Causal Link
por: Brandi, Giovanni, et al.
Publicado: (2022)

Novel Targeted Therapies for Advanced Cholangiocarcinoma
por: Rizzo, Alessandro, et al.
Publicado: (2021)

The protease‐inhibitor SerpinB3 as a critical modulator of the stem‐like subset in human cholangiocarcinoma
por: Correnti, Margherita, et al.
Publicado: (2021)

Improvements in Systemic Therapies for Advanced Malignant Mesothelioma
por: Deiana, Chiara, et al.
Publicado: (2023)

Adjuvant treatment in biliary tract cancer
por: Palloni, Andrea, et al.
Publicado: (2019)

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
por: Rizzo, Alessandro, et al.
Publicado: (2021)

Is post‐transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases?
por: Brandi, Giovanni, et al.
Publicado: (2020)

Survival trends over 20 years in patients with advanced cholangiocarcinoma: Results from a national retrospective analysis of 922 cases in Italy
por: Casadei-Gardini, Andrea, et al.
Publicado: (2023)

PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
por: Ricci, Angela Dalia, et al.
Publicado: (2020)

Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study
por: Vasuri, Francesco, et al.
Publicado: (2023)

Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges
por: Rizzo, Alessandro, et al.
Publicado: (2020)

Intensive Follow-Up Program and Oncological Outcomes of Biliary Tract Cancer Patients after Curative-Intent Surgery: A Twenty-Year Experience in a Single Tertiary Medical Center
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Hot topics in cholangiocarcinoma
por: Brandi, Giovanni
Publicado: (2019)

Targeting tumor microenvironment for cholangiocarcinoma: Opportunities for precision medicine
por: Carloni, Riccardo, et al.
Publicado: (2022)

Gene Expression Signature Predictive of Neuroendocrine Transformation in Prostate Adenocarcinoma
por: Ostano, Paola, et al.
Publicado: (2020)

Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma
por: Carloni, Riccardo, et al.
Publicado: (2023)

Wilson disease, ABCC2 c.3972C > T polymorphism and primary liver cancers: suggestions from a familial cluster
por: Brandi, Giovanni, et al.
Publicado: (2020)

Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database Analysis
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Heterogeneity of Cholangiocarcinoma Immune Biology
por: Vita, Francesca, et al.
Publicado: (2023)

Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes
por: Di Federico, Alessandro, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ho8b2net9gt0cpb1taah6vhrre